The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
The facility sets a new benchmark in respiratory diagnostics
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
